Checkpoint Therapeutics Inc (NASDAQ:CKPT)
| 5.16 Delayed Data As of Jan 26 |  0.00 / 0.00%Today’s Change | 3.56 Today|||52-Week Range 27.00 | +0.98% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $51.8M |
Company Description
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
Contact Information
Checkpoint Therapeutics, Inc. 95 Sawyer Road Waltham Massachusetts 02453 |
Employees
Shareholders
| Other institutional | 8.58% |
| Mutual fund holders | 5.74% |
| Individual stakeholders | 20.33% |
Top Executives
| James F. Oliviero | President, Chief Executive Officer & Director |
| William Garrett Gray | Chief Financial Officer, Secretary & Treasurer |
| Jaclyn Jaffe | Head-Investor Relations |
